Case 1 Ms A is a 27-year-old woman with BPD and a longstanding history of suicide attempts, self-injury and multiple psychiatric hospitalizations, admitted after being found on a bridge stating she intended to jump and end her life. This Veliparib clinical trial occurred shortly after her release from another hospital where she had been admitted after slashing her wrists. Ms A’s first hospitalization occurred at age 16 after she overdosed on pills; she had approximately nine lifetime admissions. Her first instance of self-injury (cutting and burning herself) occurred at the age

of eight. Ms A endorsed suicidal intent consistently throughout the first weeks of her hospitalization. Inhibitors,research,lifescience,medical She had several episodes of cutting herself and assaulting other patients, requiring manual holds and seclusion. On one occasion she was found with a bed sheet Inhibitors,research,lifescience,medical tied into a noose with a plan to hang herself. She required 1:1 observation by staff for a duration of eight weeks. Antidepressant and mood-stabilizing medication provided no benefit. Clozapine was initiated and brought to 150 mg daily (blood level 190 ng/ml). After 3 weeks of clozapine treatment, Ms A reported significant

improvement in mood and anxiety, and decreased frequency and intensity of suicidal thoughts; 1:1 observation was discontinued 4 weeks after initiation of clozapine. After clozapine, Inhibitors,research,lifescience,medical Ms A had only one instance of aggression and one instance of self-injury. She was ready for discharge 7 weeks after starting clozapine and has not been readmitted to the state hospital since. Inhibitors,research,lifescience,medical Case 2 Ms B is a 41-year-old female who was admitted after she cut her neck with a knife in a suicide attempt. Ms B has had approximately 15 hospitalizations over the prior 20 years, with multiple suicide attempts and self-injurious episodes in that time. She has overdosed on medications, made deep cuts to her body requiring surgical intervention and has a history of head banging. Ms B required 1:1 observation on admission due to her repeated self-injurious actions. She had frequent instances of head banging and was aggressive towards staff members. She

denied any Inhibitors,research,lifescience,medical psychotic symptoms during this hospitalization. She required numerous Endonuclease manual holds and required four-point restraints on eight separate occasions. The patient had only a modest response to antipsychotic, antidepressant and anti-anxiety medications. Ms B was started on clozapine. The dose was brought to 400 mg daily (clozapine level 208 ng/ml). One week after clozapine was initiated there was a noticeable decline in Ms B’s level of aggression and agitation; 2 weeks following initiation of clozapine, 1:1 observation was successfully discontinued. There were no holds, seclusions or restraints required after approximately 1 week of clozapine therapy. Ms B was discharged from the hospital 1 month after clozapine was initiated and she has not been readmitted to a state facility in over one year.